Study of Clinical Features and Efficacy of Small Intestinal Bacterial Overgrowth in Patients With Abdominal Distension

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Small Intestine Bacterial Overgrowth
Interventions
DRUG

Rifaximin

Both groups were treated with rifaximin for 14 days, during which follow-up records were reported by the subjects in the daily reference case report form. Methane and hydrogen breath tests were repeated 2 weeks after withdrawal.

All Listed Sponsors
collaborator

Navy General Hospital, Beijing

OTHER

collaborator

Air Force Military Medical University, China

OTHER

collaborator

Beijing Tongren Hospital

OTHER

collaborator

Beijing Friendship Hospital

OTHER

collaborator

Beijing Chao Yang Hospital

OTHER

collaborator

Beijing Tiantan Hospital

OTHER

collaborator

The Luhe Teaching Hospital of the Capital Medical University

OTHER

collaborator

China-Japan Friendship Hospital

OTHER

collaborator

Beijing Aerospace General Hospital

OTHER

collaborator

Beijing Jishuitan Hospital

OTHER

collaborator

Peking University Third Hospital

OTHER

lead

Peking Union Medical College Hospital

OTHER

NCT06518850 - Study of Clinical Features and Efficacy of Small Intestinal Bacterial Overgrowth in Patients With Abdominal Distension | Biotech Hunter | Biotech Hunter